SCHEMBL9513437

SCHEMBL9513437

CCCC(CCC)(CNC(N)=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 1/20 0.45
CHRM2 P08172 2/20 0.43
CHRM1 P11229 2/20 0.43
CHRM3 P20309 2/20 0.43
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
LMNA P02545 5/20 0.40
BCAT2 O15382 1/20 0.39
CYP2C19 P33261 4/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39
ALOX12 P18054 1/20 0.39
CYP2D6 P10635 3/20 0.37
SCN1A P35498 3/20 0.37
SCN2A Q99250 3/20 0.37
SCN3A Q9NY46 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9514978 0.91 KIF11 (0.44) CACNA1GCHRM2CHRM1CHRM3KMT2A
SCHEMBL9513462 0.87 CHRM2 (0.45) CACNA1GCHRM2CHRM1CHRM3KMT2A
SCHEMBL4231538 0.77 BCAT2 (0.47) CHRM2CHRM1CHRM3KMT2AMAPT
SCHEMBL9517017 0.76 MAPT (0.50) CHRM2CHRM1CHRM3KMT2AMAPT
SCHEMBL20909439 0.75 BCAT2 (0.46) CHRM2CHRM1CHRM3KMT2AMAPT
SCHEMBL5161794 0.75 HPGD (0.56) KMT2ALMNARAB9AMEN1
SCHEMBL9447623 0.74 KCNN4 (0.44) LMNACYP2C19CYP2D6SCN1ASCN2A
SCHEMBL5159280 0.74 CYP2C19 (0.55) KMT2AMAPTLMNACYP2C19HTT
SCHEMBL3901654 0.74 LMNA (0.48) CHRM2CHRM1CHRM3KMT2AMAPT
SCHEMBL8480813 0.73 CYP2C19 (0.44) KMT2AMAPTLMNACYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0344425-B1 N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents WARNER LAMBERT CO (US) 1993-12-08 EP claimed
EP-0344425-A2 N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents WARNER-LAMBERT COMPANY (US) 1989-12-06 EP claimed
EP-0344425-B1 N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents WARNER LAMBERT CO (US) 1993-12-08 EP disclosed
EP-0344425-A2 N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents WARNER-LAMBERT COMPANY (US) 1989-12-06 EP disclosed